Adalvo Drug Patent Portfolio
Adalvo owns 1 orange book drug protected by 4 US patents Given below is the list of Adalvo's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9579288 | Tesofensine and beta blocker combination formulations | 23 Jul, 2027 | Active |
| US9597288 | Transmucosal delivery devices with enhanced uptake | 23 Jul, 2027 | Active |
| US7579019 | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces | 22 Jan, 2020 | Expired |
| US6159498 | Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces | 18 Oct, 2016 | Expired |
Latest Legal Activities on Adalvo's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Adalvo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 27 Sep, 2021 | US7579019 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 12 Apr, 2021 | US7579019 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Sep, 2020 | US9597288 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 14 Aug, 2020 | US9579288 |
| Review Certificate Mailed | 08 Feb, 2018 | US7579019 (Litigated) |
| Review Certificate | 15 Dec, 2017 | US7579019 (Litigated) |
|
Patent Issue Date Used in PTA Calculation
Critical
| 21 Mar, 2017 | US9597288 |
|
Recordation of Patent Grant Mailed
Critical
| 21 Mar, 2017 | US9597288 |
|
Email Notification
Critical
| 02 Mar, 2017 | US9597288 |
|
Issue Notification Mailed
Critical
| 01 Mar, 2017 | US9597288 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 28 Feb, 2017 | US9579288 |
|
Recordation of Patent Grant Mailed
Critical
| 28 Feb, 2017 | US9579288 |
| Dispatch to FDC | 10 Feb, 2017 | US9597288 |
|
Application Is Considered Ready for Issue
Critical
| 09 Feb, 2017 | US9597288 |
|
Email Notification
Critical
| 09 Feb, 2017 | US9579288 |
Adalvo's Drug Patent Litigations
Adalvo's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 22, 2014, against patent number US7579019. The petitioner MONOSOL RX, LLC, challenged the validity of this patent, with Arius Two, Inc. as the respondent. Click below to track the latest information on how companies are challenging Adalvo's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7579019 | January, 2014 |
FWD Entered
(05 Aug, 2015)
| Arius Two, Inc. | MONOSOL RX, LLC |
Adalvo's Family Patents
Adalvo Drug List
Given below is the complete list of Adalvo's drugs and the patents protecting them.
1. Onsolis
Onsolis is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9579288 | Tesofensine and beta blocker combination formulations |
23 Jul, 2027
(2 years from now)
| Active |
| US9597288 | Transmucosal delivery devices with enhanced uptake |
23 Jul, 2027
(2 years from now)
| Active |
| US7579019 | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
22 Jan, 2020
(4 years ago)
| Expired |
| US6159498 | Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces |
18 Oct, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onsolis's drug page